GLP-1 Receptor Agonist Research Update for Metabolic Health

Unlock the potential of GLP-1 receptor agonists for metabolic health to manage obesity and improve your metabolic outcomes.

Abstract

In this educational post, I will guide you through the transformative and evolving world of Glucagon-Like Peptide-1 (GLP-1) receptor agonists. We will explore the past, present, and future of these remarkable medications, which have fundamentally changed the way we approach metabolic diseases such as type 2 diabetes and obesity. We’ll begin with a historical overview, tracing their origins from Gila monster saliva to today’s highly effective treatments. Then, we will delve into the intricate physiological mechanisms, explaining how these agents work in the pancreas, brain, cardiovascular system, and gut to regulate blood sugar, suppress appetite, and promote weight loss. We will discuss groundbreaking clinical trial data supporting their use and highlight impressive benefits for weight management, cardiovascular health, and kidney protection.

A significant portion of this post is dedicated to safety, covering common side effects, the “start low, go slow” dosing strategy, and emerging concerns like recent FDA safety alerts and perioperative management protocols. We’ll also examine critical drug interactions, their use in special populations, and the realities of long-term use and discontinuation. Finally, I will explain how integrative chiropractic care complements these therapies, emphasizing a holistic approach that supports musculoskeletal health, nervous system function, and overall well-being for patients on this journey to metabolic recovery.

Hello, I’m Dr. Alex Jimenez. With my background in chiropractic (DC), as an advanced practice registered nurse and family nurse practitioner (APRN, FNP-BC), and with certifications in functional medicine (CFMP, IFMCP), advanced technology (ATN), and clinical certification in spinal trauma (CCST), I am passionate about integrating the best of evidence-based medicine to help my patients achieve optimal health. My clinical observations at the PushasRx wellness facility have consistently shown me that conditions like obesity and type 2 diabetes are not isolated issues but are deeply intertwined with our overall physiology, from our musculoskeletal structure to our hormonal balance.

Obesity is a major public health crisis in the United States, with over 40% of adults affected—a number that continues to climb. This condition is not simply a matter of excess weight; it is a powerful driver of numerous chronic diseases, including type 2 diabetes, cardiovascular disease, chronic kidney disease, stroke, and even certain cancers. Diabetes alone impacts roughly 11% of the U.S. population, with obesity being a primary contributor.

When lifestyle changes such as diet and exercise are not sufficient, we now have powerful pharmacologic tools to support patients on their journey toward metabolic health. Among the most significant breakthroughs are the anti-obesity medications (AOMs), particularly the class known as GLP-1 receptor agonists. Originally developed to manage blood sugar, these agents have proven exceptionally effective for weight loss and are now considered first-line treatments for both diabetes and obesity management, supported by robust evidence and cardiometabolic benefits.

In this post, I want to take you on an educational journey, drawing on the latest findings from leading researchers to demystify these therapies. We will explore how they work, when to consider them, and how to create an individualized, holistic treatment plan that ensures safety and efficacy.

Decoding the Language of Metabolic Hormones

Before we dive deeper, it’s essential to understand a few key terms that are central to this discussion. These abbreviations are common in clinical research and will help you follow the science behind these innovative treatments.

• GCG (Glucagon): While often known as the hormone that counteracts insulin to raise blood sugar, glucagon also plays a vital role in energy balance, appetite regulation, and controlling glucose production in the liver. This becomes particularly relevant as we look at newer dual- or triple-agonist therapies.
• NSHT (Nutrient-Stimulated Hormone Therapies): A descriptive category of treatments that mimic the body’s natural hormonal response to eating. Therapies like GLP-1 and GIP agonists fall under this umbrella, as they target gut-derived hormones to modulate appetite, insulin secretion, and weight.
• GLP-1 (Glucagon-Like Peptide-1): This is the star of our discussion. GLP-1 is a natural hormone produced in the gut in response to food. GLP-1 receptor agonists are medications that mimic the action of this hormone. You will see these terms used interchangeably.
• GIP (Glucose-Dependent Insulinotropic Polypeptide): Previously known as gastric inhibitory peptide, GIP is another crucial gut hormone that works in synergy with GLP-1. It enhances insulin secretion and supports energy storage. Newer co-agonist medications, such as tirzepatide, target both GLP-1 and GIP receptors to achieve a more potent effect.

Understanding this hormonal language is the first step toward appreciating the sophisticated science behind these therapies.

The Multifaceted Mechanism of GLP-1 Receptor Agonists

When I first began studying GLP-1 receptor agonists, the focus was almost entirely on their role in diabetes management, specifically their effects on the pancreas. However, we now know that their influence is far more widespread. GLP-1 receptors are found throughout the body, including the kidneys, the cardiovascular system, and, critically, the central nervous system. This systemic action is what makes them so powerful.

Here’s a breakdown of how they work in different parts of the body:

• In the Pancreas, GLP-1 agonists stimulate beta-cell insulin secretion in a glucose-dependent manner. This is a key safety feature—they primarily work when blood sugar is high, reducing the risk of hypoglycemia compared to older diabetes medications. Simultaneously, they suppress the alpha cells from releasing glucagon, which in turn reduces the liver’s production of excess glucose.
• In the Gastrointestinal (GI) Tract: A major effect is the delay of gastric emptying. By slowing down how quickly food leaves the stomach, these medications promote a prolonged feeling of fullness, or satiety, which naturally leads to reduced food intake.
• In the Central Nervous System (CNS), GLP-1 agonists cross the blood-brain barrier and act on the hypothalamus, the brain’s control center for appetite. This direct action helps to decrease hunger signals. Furthermore, they influence the ventral tegmental area, a key part of the brain’s reward pathway. By dampening the dopamine response associated with eating, particularly highly palatable foods, they can help reduce cravings and the cycle of overeating.
• In the Cardiovascular and Renal Systems, the benefits are profound. Clinical trials have consistently shown that these medications have a cardioprotective effect, significantly reducing the risk of major adverse cardiovascular events (MACE) such as heart attacks and strokes. They also demonstrate a renoprotective effect, slowing the progression of chronic kidney disease.

This multifaceted mechanism illustrates why GLP-1 agonists are not just “diabetes drugs” or “weight-loss drugs” but true metabolic regulators.

A Journey Through Time: The History of GLP-1 Therapies

The story of GLP-1 agonists is a fascinating example of how nature can inspire medical innovation. The journey began in the 1980s with the discovery of incretin hormones, but the first therapeutic breakthrough came in 2005 with the approval of exenatide (Byetta). What’s truly remarkable is that exenatide was derived from the saliva of the Gila monster. This desert lizard’s venom contains a peptide that is resistant to breakdown in the body, making it a perfect model for a long-acting GLP-1 therapy.

From there, the field rapidly evolved:

• 2009: Liraglutide (Victoza) was approved, becoming the first GLP-1 analog structurally similar to the human hormone.
• 2012: A once-weekly version of exenatide was introduced, making treatment more convenient for patients.
• 2017: This was a watershed year with the arrival of semaglutide (Ozempic). This once-weekly injectable offered superior A1c reduction and weight loss benefits, and extensive marketing brought GLP-1 agonists into the public spotlight.
• 2021: A higher-dose formulation of semaglutide, Wegovy, was approved specifically for chronic weight management.
• 2022: Tirzepatide (Mounjaro, Zepbound) became the first dual-action GIP/GLP-1 receptor agonist, offering even more significant weight loss and glycemic control.

Today, the research pipeline is filled with exciting possibilities, including triple-agonist agents (targeting GLP-1, GIP, and glucagon), novel oral formulations, and combination therapies. The focus is expanding beyond diabetes and obesity to include conditions like heart failure, kidney disease, and even neurodegenerative and psychiatric disorders.

The Evidence Speaks: Landmark Clinical Trial Outcomes

The widespread adoption of these medications is built on a mountain of compelling, evidence-based research. Let’s look at some of the key trials that have defined their use:

• SCALE Trial (Liraglutide): This study demonstrated that patients on liraglutide achieved an average of 8% body weight loss after 56 weeks, establishing a new standard for anti-obesity medications at the time.
• STEP Trials (Semaglutide): This series of trials was a game-changer.

• • STEP 1: In patients with obesity but without diabetes, semaglutide led to an average weight loss of nearly 15% after 68 weeks.
  • STEP 2: In patients with type 2 diabetes, it resulted in an average weight loss of 6% and a significant A1c reduction of 1.6%.

• SURMOUNT Trials (Tirzepatide): The dual-agonist tirzepatide pushed the boundaries even further.

• • SURMOUNT-1: Patients with obesity saw an astonishing average weight loss of up to 9% at 72 weeks.
  • SURMOUNT-2: In patients with type 2 diabetes, it resulted in up to 7% weight loss and a remarkable A1c reduction of over 2.1%.

Beyond weight loss and blood sugar, other trials have confirmed the broader systemic benefits:

• SELECT Trial (Semaglutide): This landmark study involved patients with pre-existing cardiovascular disease and obesity but without diabetes. It found a 20% reduction in major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, and non-fatal stroke).
• STEP-HFpEF Trial (Semaglutide): In patients with obesity and heart failure with preserved ejection fraction (HFpEF), semaglutide led to significant improvements in heart failure symptoms, physical limitations, and exercise function.
• FLOW Trial (Semaglutide): Results announced in 2024 showed that semaglutide reduced the risk of major kidney disease events by 24% in people with type 2 diabetes and chronic kidney disease.

This robust body of evidence firmly establishes GLP-1 receptor agonists as essential tools for managing complex metabolic disease.

Navigating Safety: Adverse Effects and Contraindications

As with any powerful medication, a thorough understanding of safety is paramount. From my clinical experience, proactive patient education and a careful “start low, go slow” titration strategy are the keys to successful treatment.

Common Adverse Effects:

The most frequently reported side effects are gastrointestinal, stemming from the delayed gastric emptying. These include:

• Nausea (most common)
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain and dyspepsia

These effects are typically mild to moderate and often subside as the body adapts to the medication. Titrating the dose up gradually is crucial to minimizing these issues.

Serious but Rare Adverse Effects:

• Pancreatitis: There is an increased risk of acute pancreatitis. Patients should be counseled to report severe, persistent abdominal pain that may radiate to the back.
• Gallbladder Disease: Cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) have been reported, likely related to rapid weight loss.
• Bowel Obstruction/Gastroparesis: Given their effect on GI motility, these drugs can, in rare cases, lead to or worsen gastroparesis (paralyzed stomach) or cause a bowel obstruction.
• Hypoglycemia: The risk is low when used alone, but it increases significantly when combined with other diabetes medications that can cause low blood sugar, like insulin or sulfonylureas (e.g., glipizide). Dose adjustments of these other medications are often necessary.
• Loss of Lean Muscle Mass: Rapid weight loss can involve the loss of both fat and muscle. This is where adjunctive therapies like resistance training and ensuring adequate protein intake become critical.

The U.S. Boxed Warning: Understanding the Thyroid Tumor Risk

All GLP-1 receptor agonists carry a U.S. Boxed Warning regarding the potential risk of thyroid C-cell tumors, specifically Medullary Thyroid Carcinoma (MTC).

This warning stems from preclinical studies in rodents, in which these drugs caused a dose- and duration-dependent increase in tumor size. However, it is crucial to understand that the relevance of this finding to humans is unknown. Rodents have a much higher density of GLP-1 receptors on their thyroid C-cells than humans do, making them uniquely susceptible.

Due to this theoretical risk, these medications are contraindicated in patients with:

• A personal or family history of MTC.
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) is a genetic disorder that predisposes individuals to MTC.

As clinicians, our duty is to screen every patient for these contraindications and to educate them on the symptoms of a potential thyroid mass, such as a palpable neck lump, difficulty swallowing, or persistent hoarseness. The FDA does not currently recommend routine monitoring with calcitonin levels or thyroid ultrasounds.

Emerging Safety Concerns and FDA Alerts for GLP-1 Agonists

As healthcare providers, it’s our responsibility to stay vigilant about the safety and integrity of the medications we prescribe. Recently, several emerging issues with GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have come to light.

• Compounding and Counterfeit Risks: There have been reports of errors in preparation and measurement from compounding pharmacies. More alarmingly, the rise of illegal marketing of counterfeit products and unregulated online sales poses a serious public health threat. Patients seeking cheaper alternatives may unknowingly purchase “research use only” products that are not safe for human consumption. We must educate our patients to use only FDA-approved medications dispensed by licensed pharmacies. Medication safety is as crucial as its efficacy.
• FDA Safety Alert on Suicidal Ideation: In 2024, the FDA issued a special alert to evaluate reports of suicidal thoughts or behaviors in patients using GLP-1 receptor agonists for weight management. It is crucial to understand that, at this time, a preliminary review has not found a causal link. However, the seriousness of this concern requires our attention. As practitioners, we must be proactive in screening for and monitoring mental health, especially in patients with a history of mood disorders, depression, or eating disorders, which often co-occur with obesity. While there are no formal contraindications based on this risk yet, careful counseling and monitoring are essential.

Eating Right to Feel Better- Video

Navigating Perioperative Care with GLP-1 Receptor Agonists

A significant area of discussion is how to manage patients on these medications when they are scheduled for surgery. In 2024, a consensus statement was released by several major organizations, including the American Society of Anesthesiologists and the American Gastroenterological Association.

The primary concern stems from the core mechanism of GLP-1 receptor agonists: they delay gastric emptying. This physiological effect, while beneficial for satiety and glycemic control, can increase the risk of pulmonary aspiration during anesthesia induction because residual food may remain in the stomach.

Here is the key guidance:

• Most patients can safely continue their GLP-1 therapy before surgery.
• High-risk patients, particularly those experiencing significant nausea, vomiting, or diagnosed with gastroparesis, should follow a pre-procedure liquid diet to minimize aspiration risk.

As a clinician involved in perioperative clearance, I always make it a point to ask about GLP-1 use during my pre-op assessments. This allows for proper coordination with anesthesia teams to ensure patient safety and to individualize the plan based on GI symptoms and the specific surgical procedure.

Critical Drug Interactions to Monitor

When prescribing GLP-1 receptor agonists, understanding potential drug interactions is vital for patient safety. There are four major categories to be aware of.

1. Concurrent Diabetes Medications:

• • Insulin and Sulfonylureas: Combining GLP-1 agonists with insulin or sulfonylureas (e.g., glimepiride, glyburide) significantly increases the risk of hypoglycemia. The mechanism is straightforward: GLP-1 agonists promote feelings of fullness, leading to reduced food intake. Less food means less glucose entering the system. A previously appropriate dose of insulin or a sulfonylurea may now be excessive. The proactive approach is to consider reducing the doses of these concomitant medications when initiating a GLP-1 agonist.

• Narrow Therapeutic Index (NTI) Drugs:

• • Because GLP-1 agonists slow gastric emptying, they can potentially delay or reduce the absorption of other orally administered drugs. This is particularly concerning for NTI drugs (like warfarin, digoxin, or certain anti-epileptics) where small changes in concentration can lead to toxicity or loss of efficacy. More frequent monitoring is required during the initiation and dose escalation phases of GLP-1 therapy.

• Oral Contraceptives (Tirzepatide Specific):

• • The dual-acting GLP-1/GIP receptor agonist, tirzepatide, has a specific warning regarding oral contraceptives. The package insert recommends using a non-oral contraceptive method for four weeks after starting the medication and for four weeks after each dose escalation. This is not a stated concern for other GLP-1 agonists, but it’s a critical counseling point for patients on tirzepatide.

• DPP-4 Inhibitors:

• • Dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., sitagliptin/Januvia) work by increasing the half-life of the body’s natural, or endogenous, GLP-1 and GIP. In theory, combining them with a GLP-1 receptor agonist might seem to boost effectiveness. However, the American Diabetes Association recommends avoiding this combination. Clinical evidence has shown it does not provide significant additional benefit and, in fact, increases the risk of side effects.

Use in Special Populations and Long-Term Considerations

The application of these powerful agents extends to various patient groups, but specific precautions are necessary.

• Pediatrics: Two GLP-1 receptor agonists are now FDA-approved for weight management in adolescents aged 12 and older. The American Academy of Pediatrics supports their use for obesity in this age group, always in conjunction with comprehensive lifestyle modifications.
• Pregnancy and Breastfeeding: Use of GLP-1 receptor agonists is not recommended during pregnancy or while breastfeeding. It is advised that patients use effective contraception during therapy and for up to two months after discontinuation.

A crucial question many patients ask is, “What happens if I stop taking the medication?” Obesity, much like hypertension or dyslipidemia, is a chronic disease. Research is demonstrating that these medications are likely needed for long-term management.

• The STEP 1 trial extension found that one year after withdrawing from semaglutide, participants regained roughly two-thirds of their prior weight loss.
• The SURMOUNT-4 trial showed that patients who continued tirzepatide after an initial 36-week period continued to lose weight. At the same time, those switched to a placebo experienced a 14% mean weight regain over the next year.

This data strongly suggests that cessation of therapy often leads to weight regain, reinforcing the concept of obesity as a chronic condition requiring ongoing treatment.

Addressing High Discontinuation Rates Through Patient Education

Despite their proven benefits—significant A1C reduction, substantial weight loss, and cardiovascular and renal protection—discontinuation rates for GLP-1 agonists are alarmingly high. One study revealed that nearly 50% of patients with type 2 diabetes and almost 65% of patients using them for weight loss stop within the first year.

The top reasons for discontinuation are:

1. Adverse effects
2. Multiple reasons
3. Cost

This is where we, as providers, can make a profound difference. It is a clinical disservice for a patient to stop a beneficial medication due to manageable side effects they were not properly educated about. Our role is to be proactive. Are we starting at the lowest dose and titrating slowly? Have we thoroughly educated patients on what to expect and provided them with strategies to manage GI side effects? Empowering patients with this knowledge is a cornerstone of improving adherence and long-term success.

Clinical Case Study: Restarting Semaglutide Safely

Let’s consider a common clinical scenario.

Patient: Ms. Amanda Chen, a 58-year-old woman with type 2 diabetes, obesity (BMI 36), and osteoarthritis.

History: She was prescribed semaglutide and successfully titrated to 1.7 mg weekly, losing 12 pounds with good tolerance. However, she stopped the medication six weeks ago due to a prolonged GI illness.

Today’s Visit: She feels better and is eager to restart semaglutide at her previous dose of 1.7 mg.

This scenario poses several critical questions. The most important question is: Why must she restart at the lowest dose?

The correct and safe approach is to restart Ms. Chen at the initial dose of 0.25 mg weekly and follow the standard titration schedule again.

The Physiological Rationale: The body’s tolerance to the GI effects of GLP-1 agonists, particularly the delayed gastric emptying, resets after the medication has been stopped for several weeks. Restarting at a high dose after such an interruption dramatically increases the risk of severe nausea, vomiting, and other GI side effects, which could lead to poor adherence or even more serious complications like pancreatitis.

Titration and Monitoring Schedule for Ms. Chen:

• Restart:25 mg weekly for 4 weeks.
• Escalate: Increase to 0.5 mg for 4 weeks, then 1.0 mg for 4 weeks, and so on, as tolerated, until reaching the maintenance dose.
• Monitoring: During this dose-escalation phase, I would see her monthly to monitor her tolerance, weight changes, and any GI side effects. Once stable, follow-ups can be quarterly. We would also closely monitor her nutritional status, given her recent illness.

The Integral Role of Nutrition and Physical Activity

Success with GLP-1 receptor agonists is not just about the medication; it is about a holistic, lifestyle-integrated approach. As a practitioner who values functional and integrative care, I emphasize this with every patient.

A helpful framework for nutritional counseling is the MEAL mnemonic, proposed by Murtagh et al. (2025):

• M – Muscle Maintenance: Encourage adequate protein intake (1.0-1.5 g/kg of ideal body weight) and resistance training to prevent the loss of lean body mass during weight reduction.
• E – Energy Balance: Advise smaller, nutrient-dense meals spaced throughout the day to manage satiety and prevent the fatigue that can accompany calorie restriction.
• A – Avoid Side Effects: Provide practical strategies for common GI issues.

• • Constipation: Increase fiber, fluids, and physical activity.
  • Nausea: Avoid fried, greasy foods and carbonated drinks.
  • GERD: Eat smaller meals, avoid lying down after eating, and limit spicy or high-fat foods.

• L – Liquid Intake: Aim for 2-3 liters of water daily (unless contraindicated) to support hydration and GI motility.

Physical Activity Recommendations:

Movement is a non-negotiable component of therapy.

• Aerobic Activity: Build up to 150 minutes of moderate-intensity activity (e.g., brisk walking, cycling) per week.
• Resistance Training: Aim for 60-90 minutes per week, spread over 2-3 sessions, to preserve muscle mass and metabolic rate.
• Balance and Mobility: Especially for older adults, incorporating exercises that improve balance and functional strength is crucial for reducing fall risk and maintaining independence.

The Role of Integrative Chiropractic Care in Metabolic Health

As a Doctor of Chiropractic, I see the body as an interconnected system. While GLP-1 agonists are powerful pharmacological tools, they do not address the foundational musculoskeletal and biomechanical aspects of health that are critical for long-term success. This is where integrative chiropractic care becomes an invaluable partner in the patient’s journey.

• Supporting Musculoskeletal Health: Obesity places immense stress on the musculoskeletal system, leading to joint pain (especially in the knees, hips, and lower back), postural imbalances, and reduced mobility. As patients begin to lose weight and increase their physical activity, chiropractic adjustments can help:

• • Improve joint mobility and function.
  • Reduce pain and inflammation.
  • Correct postural misalignments that have developed over the years of carrying excess weight.
  • This allows patients to engage more comfortably and effectively in the exercise that is so crucial for preserving lean muscle mass and improving cardiovascular health. This is especially true for patients like Ms. Chen with co-existing osteoarthritis.

• Enhancing Nervous System Function: The spine houses and protects the nervous system, which controls every function in the body, including metabolic and digestive processes. My clinical observations at PushasRx have reinforced my belief that correcting spinal misalignments (subluxations) can optimize nerve flow. This may help support the autonomic nervous system’s regulation of gut motility and function, potentially easing some of the GI side effects associated with GLP-1 agonists.
• Guidance on Therapeutic Exercise and Nutrition: In my practice, we go beyond adjustments. We provide personalized guidance on therapeutic exercise, focusing on cardiovascular activity and, most importantly, resistance training. This is vital to counteract the potential loss of lean muscle mass during rapid weight loss. We also offer nutritional counseling to ensure patients are consuming adequate protein and micronutrients to support their changing bodies.
• A Holistic and Patient-Centered Partnership: An integrative approach creates a supportive ecosystem for the patient. While they are working with their medical provider to manage their GLP-1 therapy, their chiropractic team is helping them rebuild their body’s structural foundation, manage pain, and adopt the lifestyle habits necessary for long-term success. This partnership empowers patients and treats them as whole people, not just collections of symptoms.

By combining the powerful hormonal regulation of GLP-1 receptor agonists with the structural and functional support of integrative chiropractic care, we can offer a comprehensive, effective strategy to overcome metabolic disease and achieve lasting health and vitality.

Clinical Pearls and Pitfalls: A Summary for Success

To conclude, let’s summarize the key takeaways for effectively managing patients on GLP-1 receptor agonists.

Clinical Pearls (The “Do’s” ):

• Start with the”Why”: Select the agent based on the patient’s full clinical profile (diabetes, obesity, cardiovascular risk).
• Start Low, Go Slow: This is the golden rule for minimizing side effects and improving adherence.
• Educate Proactively: Counsel on injection technique, side effects, and management strategies.
• Monitor Closely: Watch for hypoglycemia (with other agents), pancreatitis risk, and renal function.
• Set Realistic Expectations: Weight loss is a gradual journey.
• Leverage Your Team: Work with dietitians, pharmacists, and other specialists.

Common Pitfalls (The “Don’ts” ):

• Rushing Dose Escalation: This is the most common mistake and a primary cause of discontinuation.
• Inadequate Education: Leads patients to stop therapy for avoidable reasons.
• Overlooking Drug Interactions: Especially with oral medications whose absorption may be altered.
• Ignoring Hydration: Many side effects, such as fatigue and dizziness, can improve with adequate fluid intake.
• Missing Signs of Pancreatitis: Maintain a high index of suspicion for persistent upper abdominal pain.
• Forgetting the “Set it and Forget It” Mentality: These medications require active, ongoing monitoring and partnership with the patient.

These medications are transformative tools, but their success hinges on thoughtful use, thorough patient education, and partnership in their health journey. As healthcare providers, we can connect evidence with empathy, making these therapies safe, effective, and sustainable over the long term.

Thank you for joining me on this educational journey.

References

• [Fictional reference for the 2024 Perioperative Consensus Statement as described in the transcript].
• [Fictional reference for the 2024 FDA Safety Alert as described in the transcript].
• Murtagh, M., et al. (2025). [Fictional reference for the MEAL mnemonic as described in the transcript]. Journal of Clinical Nutrition and Metabolism.
• [Fictional reference for the STEP 1 Trial Extension as described in the transcript].
• [Fictional reference for the SURMOUNT-4 Trial as described in the transcript].

Note: Specific journal and trial publication details were not provided in the source transcript and have been represented with placeholder references for structural and formatting purposes.

SEO Tags: GLP-1, Semaglutide, Tirzepatide, Weight Loss, Type 2 Diabetes, Metabolic Health, Integrative Medicine, Chiropractic Care, Obesity Treatment, Ozempic, Wegovy, Mounjaro, Cardiovascular Health, Kidney Disease, Dr. Alexander Jimenez, GLP-1 receptor agonists, weight loss medication, patient education, medication side effects, hypoglycemia risk, perioperative management, delayed gastric emptying, functional medicine, nutrition counseling, resistance training, long-term medication use, medication adherence, clinical pearls, FDA safety alert